SynthesisPloS one2020
The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.
Synthesis in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 6 syntheses or guidelines pooled it, 242 citations in OpenAlex.
- Diagnostic accuracy of circulating long noncoding RNAs in hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Diagnostic Value of Circulating microRNAs for Hepatocellular Carcinoma: Results of a Meta-analysis and Validation.Biochemical genetics · 2026Pooled it
- Diagnostic accuracy of circulating miRNAs to discriminate hepatocellular carcinoma from liver cirrhosis: a systematic review and meta-analysis.Frontiers in medicine · 2024Pooled it
- A comprehensive evaluation of full-spectrum cell-free RNAs highlights cell-free RNA fragments for early-stage hepatocellular carcinoma detection.EBioMedicine · 2023Pooled it
- Pooled it
- Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis.BioMed research international · 2020Pooled it
- Trial
- Urinary Volatile Organic Compounds as Non-Invasive Biomarkers to Distinguish Hepatocellular Carcinoma from Cirrhosis: A Multicentre Diagnostic Accuracy Study.Sensors (Basel, Switzerland) · 2026Observational
- Intratumoral but not circulating estradiol predicts postoperative survival in men with hepatocellular carcinoma.Discover oncology · 2026Article
- Exploring the Predictive Value of Circulating Cell-Free DNA Within a Multiparameter Panel for Hepatocellular Carcinoma Detection.Life (Basel, Switzerland) · 2026Article
- Proposal for Modified Alpha Fetoprotein Use in Hepatocellular Carcinoma Surveillance: Analysis of the 2018-2020 National Cancer Screening Program.Journal of Korean medical science · 2026Article
- Comparison of Sevoflurane and Desflurane on Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation: A Propensity Score-Matched Analysis.Medicina (Kaunas, Lithuania) · 2026Article
- Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD-1 Inhibitors in Advanced Hepatocellular Carcinoma.Cancer medicine · 2026Article
- A multi-centre, prospective trial of a methylation-based liquid biopsy for early detection of liver cancer in high-risk populations.Clinical and translational medicine · 2026Article
- Lateral flow immunochromatographic assay (LFIA) for tumor marker detection: technical evolution, clinical translation challenges, and future perspectives.Mikrochimica acta · 2026Review
- Quantification of DNA Methylation for Diagnosis and Monitoring of Hepatocellular Carcinoma.Journal of the American College of Surgeons · 2026Article
- The alternative splicing landscape of hepatocellular carcinoma and its potential for HCC detection.Hepatology communications · 2026Article
- Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma.Cancers · 2025Review
- Fontan-Associated Liver Disease: Trends Over Time and Relationship With Outcomes.Journal of the American Heart Association · 2025Article
- Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHepatocellular carcinoma (HCC) has become a pressing health problem facing the world today due to its high morbidity, high mortality, and late discovery. As a diagnostic criteria of HCC, the exact threshold of Alpha-fetoprotein (AFP) is controversial. Therefore, this study was aimed to systematically estimate the performance of AFP in diagnosing HCC and to clarify its optimal threshold.
methodsMedline and Embase databases were searched for articles indexed up to November 2019. English language studies were included if both the sensitivity and specificity of AFP in the diagnosis of HCC were provided. The basic information and accuracy data included in the studies were extracted. Combined estimates for sensitivity and specificity were statistically analyzed by random-effects model using MetaDisc 1.4 and Stata 15.0 software at the prespecified threshold of 400 ng/mL, 200 ng/mL, and the range of 20-100 ng/mL. The optimal threshold was evaluated by the area under curve (AUC) of the summary receiver operating characteristic (SROC).
resultsWe retrieved 29,828 articles and included 59 studies and 1 review with a total of 11,731 HCC cases confirmed by histomorphology and 21,972 control cases without HCC. The included studies showed an overall judgment of at risk of bias. Four studies with AFP threshold of 400 ng/mL showed the summary sensitivity and specificity of 0.32 (95%CI 0.31-0.34) and 0.99 (95%CI 0.98-0.99), respectively. Four studies with AFP threshold of 200 ng/mL showed the summary sensitivity and specificity of 0.49 (95%CI 0.47-0.50) and 0.98 (95%CI 0.97-0.99), respectively. Forty-six studies with AFP threshold of 20-100 ng/mL showed the summary sensitivity and specificity of 0.61 (95%CI 0.60-0.62) and 0.86 (95%CI 0.86-0.87), respectively. The AUC of SROC and Q index of 400 ng/mL threshold were 0.9368 and 0.8734, respectively, which were significantly higher than those in 200 ng/mL threshold (0.9311 and 0.8664, respectively) and higher than those in 20-100 ng/mL threshold (0.8330 and 0.7654, respectively). Furthermore, similar result that favored 400 ng/mL were shown in the threshold in terms of AFP combined with ultrasound.
conclusionAFP levels in serum showed good accuracy in HCC diagnosis, and the threshold of AFP with 400 ng/mL was better than that of 200 ng/mL in terms of sensitivity and specificity no matter AFP is used alone or combined with ultrasound.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.